Original Article
Clinical Screening as Compared with DNA Analysis in Families with Multiple Endocrine Neoplasia Type 2A
N Engl J Med 1994; 331:828-835September 29, 1994
- Abstract
Background
Multiple endocrine neoplasia type 2A (MEN-2A) is characterized by medullary thyroid carcinoma in combination with pheochromocytoma and sometimes parathyroid adenoma. Missense mutations in the RET proto-oncogene are associated with MEN-2A. Their detection by DNA analysis allows the identification of carriers of the gene, in whom the risk of medullary thyroid carcinoma is 100 percent. We compared the reliability of biochemical tests with that of DNA analysis in identifying carriers of the MEN2A gene.
Methods
Starting in 1975, we screened 300 subjects in four large families with MEN-2A for expression of the disease, using measurements of plasma calcitonin after stimulation with pentagastrin or calcium and urinary excretion of catecholamines and catecholamine metabolites. We tested for carrier status by DNA analysis, including linkage analysis, and more recently by analysis of mutations in the RET gene.
Results
Of 80 MEN2A gene carriers (in 61 of whom carrier status was proved by DNA analysis), 66 had abnormal plasma calcitonin values and medullary thyroid carcinoma. Fourteen young carriers had normal results of plasma calcitonin tests. In 8 of these 14, thyroidectomy revealed small foci of medullary thyroid carcinoma; the remaining 6 have not yet been operated on. Of the other 220 family members, 68 were found by DNA analysis not to carry the MEN2A gene. None of these 68 subjects had medullary thyroid carcinoma or pheochromocytoma; 6 had elevated plasma calcitonin concentrations and underwent thyroidectomy but had only C-cell hyperplasia.
Conclusions
Unlike biochemical tests, DNA analysis permits the unambiguous identification of MEN2A gene carriers.
Media in This Article
Figure 1
Schematic Representation of the RET Gene, Messenger RNA, and Protein.Figure 2
Pedigrees of Families A, B, C, and D with MEN-2A, Showing Family Members Who Had Medullary Thyroid Carcinoma (MTC) or Pheochromocytoma or Who Carried the MEN2A Gene as Determined by DNA Analysis.Article Activity
- Article
Multiple endocrine neoplasia type 2A (MEN-2A) is an inherited disease characterized by medullary thyroid carcinoma, pheochromocytoma, and parathyroid adenoma1,2. MEN type 2B (MEN-2B) is characterized by medullary thyroid carcinoma, pheochromocytoma, mucosal ganglioneuroma, and a marfanoid habitus3,4. In familial medullary thyroid carcinoma, medullary thyroid carcinoma occurs without the other abnormalities5-7. The pattern of inheritance of all these syndromes is autosomal dominant, with a high degree of penetrance and variable expression.
Medullary thyroid carcinoma originates in calcitonin-producing cells (C cells) of the thyroid gland8. Patients with this condition or its precursor, C-cell hyperplasia, have supranormal plasma calcitonin responses to various stimuli. In persons with MEN-2A, MEN-2B, or familial medullary thyroid carcinoma, screening for abnormal plasma calcitonin responses has permitted surgery to be performed at an early stage of the disease and has improved survival9-11. In families with MEN-2A, the biochemical manifestations of medullary thyroid carcinoma generally appear between the ages of 5 and 25 years (mean, 15) and before pheochromocytoma.
In 1987, the MEN2A gene was assigned by linkage analysis to the pericentromeric region of chromosome 10; this information allowed the reliable determination of the disease-gene carrier state12,13. In 1993, MEN-2A and familial medullary thyroid carcinoma were shown to be associated with mutations in exon 10 or 11 of the RET proto-oncogene, and specific RET mutations were detected in affected families14,15. In 1994, a unique mutation in the RET gene was identified in 48 of 50 patients from 34 families with MEN-2B16,17. The structural organization of the RET gene, as well as the predicted functional domains in the RET protein, is shown in Figure 1Figure 1
Schematic Representation of the RET Gene, Messenger RNA, and Protein. 18,19.In families with MEN-2A, the youngest generation poses an important clinical problem. Parents with medullary thyroid carcinoma are concerned about the future of their children. Biochemical screening allows tumors to be detected early, but even at this stage treatment is not always curative. Knowing that a person carries the disease gene gives an opportunity for preventive treatment. To validate DNA analysis as a reliable method for the early identification of such carriers, we compared the results of DNA analysis with those of biochemical, radiologic, and pathological examinations in four large families with MEN-2A.
Methods
Patients
Since 1974, we have repeatedly studied 300 members of four large families with MEN-2A, of whom 152 were obligate noncarriers because neither parent was affected. The studies involved a medical history, physical examination, and measurements of basal and stimulated plasma calcitonin concentrations, urinary excretion of catecholamines and catecholamine metabolites, and serum calcium concentrations. The screening examinations for family members with MEN-2A began when they were between 5 and 10 years old and were performed annually thereafter until they reached the age of 35 years, after which the examinations were performed every 3 years20. The study protocol was approved by the ethics review committee at our hospital, and the study subjects or their parents gave written informed consent.
To evaluate the yield of screening, we divided the patients into three groups. Group 1 comprised subjects who were first examined in our hospital because of symptoms or signs of medullary thyroid carcinoma, pheochromocytoma, or hyperparathyroidism. Group 2 comprised first-degree relatives of subjects in group 1 who were found to have abnormal plasma calcitonin responses to stimulation at the time of the initial screening of the family. Group 3 comprised subjects who had initially negative biochemical-test results that later became positive.
Plasma Calcitonin Stimulation Tests
Plasma calcitonin was measured before and 2 and 5 minutes after the intravenous administration of pentagastrin (0.5 μg per kilogram of body weight in 2 ml of 0.9 percent sodium chloride, given over a period of 10 seconds) or calcium (2.5 mg per kilogram, given over a period of 30 seconds)10,21,22. The test was considered positive if the peak plasma calcitonin concentration after stimulation was more than three times the basal concentration or if it was 300 ng per liter or higher. A total thyroidectomy was then performed.
Urinary Excretion of Catecholamines and Catecholamine Metabolites
Twenty-four-hour urine specimens were collected for the measurement of norepinephrine, epinephrine, total metanephrines, and vanilmandelic acid by spectrofluorometry21.
Radiologic Studies
Until 1990, computed tomographic scanning of the abdomen was performed whenever a pheochromocytoma was suspected clinically and whenever urinary catecholamine values were increased. Thereafter, 30 gene carriers who previously had normal blood-pressure and urinary catecholamine values underwent abdominal magnetic resonance imaging (MRI)23. Those who had biochemical or radiologic evidence of a pheochromocytoma underwent 131I-metaiodobenzylguanidine (MIBG) scintigraphy.
Pathological Examination
Paraffin-embedded sections of the thyroid lobes were stained with use of the immunoperoxidase or immunoalkaline phosphatase technique to detect calcitonin, chromogranin, and carcinoembryonic antigen in the C cells.
Microscopical Criteria for C-Cell Hyperplasia and Medullary Thyroid Carcinoma
The diagnosis of C-cell hyperplasia was based on the presence of an increased number of diffusely scattered C cells (i.e., ≥ 7 per thyroid follicle), clusters of C cells, or 20 or more C cells per visual field at a magnification of 200 (objective, x20; eyepiece, x10; diameter of visual field, 1 mm)8,24,25. The C cells were characterized immunohistochemically according to positivity for calcitonin, chromogranin, and carcinoembryonic antigen. Medullary thyroid carcinoma was diagnosed when nests of C cells appeared to extend beyond the basement membrane and to infiltrate and destroy thyroid follicles.
DNA Analysis
Until June 1993, we used linked genetic markers to assess the MEN2A gene carrier status of members of these families with MEN-2A26. For Southern blot analysis of markers of linked restriction-fragment-length polymorphisms, we used probes from loci FNRb27 and D10S3428 on the centromeric side of the MEN2A locus and from loci D10S102,29 RBP3,30 and D10S1531 on the distal side.
The markers from loci D10S176,32 D10S141,33 RET, and ZNF2234 detect dinucleotide-repeat polymorphisms. To demonstrate these polymorphisms, we amplified 50-ng samples of DNA by the polymerase chain reaction (PCR), in which one of the oligonucleotide primers was end-labeled with 32P-labeled ATP. The PCR products were size-fractionated on a DNA-sequencing gel that was then exposed to x-ray film for analysis.
More recently, we have identified mutations in the RET proto-oncogene by directly sequencing PCR products generated from genomic DNA isolated from peripheral-blood leukocytes with the oligonucleotide primers CRT19S (5'GCAGCATTGTTGGGGGACA3') in exon 10 and ret2190 (5'GTGGGCAAACTTGTGGTAG3') in exon 11. The amplified fragments were excised from ultra-low-melting-point agarose gels (Sigma Chemical, St. Louis). The sequences of the PCR products were determined with a pUC sequencing kit (Boehringer Mannheim, Germany) with 35S-labeled dATP (specific activity, >600 Ci per millimole). The RET mutations specific for MEN-2A create additional cleavage sites for restriction enzymes. Therefore, the presence of these mutations can also be demonstrated by restriction-enzyme digestion of PCR-amplified exons 10 and 11. The resulting DNA fragments were fractionated according to size by agarose-gel electrophoresis.
Results
DNA Analysis
The MEN2A gene carrier state could be identified with a high degree of reliability by linkage analysis using flanking DNA markers in all 129 subjects studied (68 noncarriers and 61 carriers). Sequence analysis of PCR-amplified exons 10 and 11 of the RET gene revealed three different mutations of a single allele in the probands of the four families (Figure 1). Among the other family members, MEN2A gene carriers were identified by appropriate restriction-enzyme digestion of the PCR products. These results agreed with those of the linkage analysis in all instances.
In the probands of Families A and B, thymine was replaced by cytosine at position 2095 from the starting site of transcription (T2095C), resulting in the replacement of a cysteine residue by arginine at codon 634 (C634R). In the proband of Family C, cytosine was replaced by guanine at position 2097 (C2097G), resulting in the replacement of the same cysteine residue at codon 634 by tryptophan (C634W). In the proband of Family D, cytosines at positions 2097 and 2098 were both replaced by guanines (CC2097/2098GG), affecting codons 634 and 635. The cysteine at codon 634 was replaced by tryptophan and the arginine at codon 635 by glycine (C634W/R635G). The presence of all four mutations was confirmed by restriction-enzyme analysis. The C634R mutation introduces a CfoI restriction site, and the C634W/R635G mutation a BmyI restriction site. The C634W mutation was also confirmed by using a primer with one mismatch that, in combination with the C634W mutation, disrupts a BanI restriction site.
Screening for Medullary Thyroid Carcinoma
Biochemical and radiologic tests, pathological examinations, and DNA analysis resulted in the identification of 80 subjects with MEN-2A (Table 1Table 1
Clinical Results for Subjects with MEN-2A in Four Families Diagnosed by Biochemical, Radiologic, and Pathological Studies and DNA Analysis. and Figure 2Figure 2Pedigrees of Families A, B, C, and D with MEN-2A, Showing Family Members Who Had Medullary Thyroid Carcinoma (MTC) or Pheochromocytoma or Who Carried the MEN2A Gene as Determined by DNA Analysis.). Of 14 subjects who initially presented with symptoms (group 1), 8 are alive, 3 died of metastatic medullary thyroid carcinoma (Family A, Subject V-1, and Family B, Subjects IV-3 and V-5), 2 died of pheochromocytoma (Family C, Subjects II-6 and III-6), and 1 died of a myocardial infarction (Family C, Subject III-1).During the first biochemical screening in the 52 subjects with no symptoms, 39 had abnormal results (group 2). Currently, only 15 of these subjects have normal test results. Among the remaining 24 subjects, all of whom had increased plasma calcitonin concentrations after thyroidectomy, 4 died of metastatic medullary thyroid carcinoma (Family A, Subjects IV-6, IV-13, V-2, and V-39) and 2 died of other causes (Family A, Subject IV-22, and Family D, Subject III-5).
Thirteen subjects (group 3) had initially normal results of plasma calcitonin stimulation tests that later became positive. Most of these 13 subjects had moderate increases in plasma calcitonin after stimulation for several years before the test became positive by our definition. The age of subjects at the time of conversion to a positive test result and at the onset of progressive disease was not predictable. After total thyroidectomy, nearly all subjects in group 3 remained disease-free; only one (Family B, Subject V-9, who once missed an annual examination) had recurrent disease. The results of the plasma calcitonin stimulation tests performed annually after thyroidectomy were normal in 14, 38, and 92 percent of the subjects in groups 1, 2, and 3, respectively.
Fourteen family members who were MEN2A gene carriers had negative or equivocal stimulation-test results. Eight of them, who were between 4 and 18 years of age, underwent total thyroidectomy on the basis of the DNA analysis, including screening for family-specific RET mutations (Family A, Subjects VI-23, VI-25, and VI-26, and Family B, Subjects VI-4, VI-7, VI-8, VI-9, and VI-10). The other six MEN2A gene carriers were scheduled for surgery at this writing (Family A, Subjects VI-4, VI-5, and VI-16; Family B, Subject V-14; and Family D, Subjects V-9 and V-13) (Table 1 and Figure 2).
Pathological Findings in Thyroid Glands of Asymptomatic MEN2A Gene Carriers
Sections of thyroid tissue from the eight subjects who underwent total thyroidectomy on the basis of the DNA analysis alone revealed C-cell hyperplasia (Figure 3AFigure 3
Immunohistochemical Staining of Thyroid Tissue Removed because the Subject Carried the MEN2A Gene or Had Positive Results of Calcitonin Stimulation Tests.) and scattered, generally small, irregular foci of medullary thyroid carcinoma (Table 2Table 2
Pathological Findings in the Thyroid Glands of Eight Asymptomatic MEN2A Gene Carriers, All of Whom Had Carcinoma, and Six Family Members with False Positive Results on Plasma Calcitonin Stimulation Tests Who Proved Not to Be Gene Carriers. and Figure 3B, Figure 3C, Figure 3D, and Figure 3E). Destruction of thyroid follicular structures by invading clusters of tumor cells was seen in all specimens (Figure 3B, Figure 3C, Figure 3D, and Figure 3E). The carcinomas were composed of medium-sized round, oval, or spindle-shaped cells containing abundant eosinophilic cytoplasm and vesicular nuclei with prominent nucleoli. There was mild nuclear pleomorphism, but mitoses were very rare. Highly vascular stroma was seen within the nests of tumor cells, and some contained foci of calcification. No amyloid was demonstrable by Congo-red staining in any sections. The tumor cells stained with antibodies to calcitonin, carcinoembryonic antigen (Figure 3B, Figure 3D, and Figure 3E), and chromogranin (Figure 3A). Areas of thyroid tissue adjacent to the nests of tumor cells contained more C cells that stained for calcitonin than were found in regions free of tumor.Screening for Pheochromocytoma
According to the results of biochemical and radiologic tests, 39 of the 80 affected subjects (49 percent) had pheochromocytomas, most of them bilateral. In rare cases, a pheochromocytoma developed earlier than medullary thyroid carcinoma (Family A, Subject VI-4, and Family B, Subject V-14).
Thirty MEN2A gene carriers in whom blood pressure and urinary excretion of catecholamines were not elevated underwent abdominal MRI. Six of them had abnormalities of one or both adrenal glands. In all six, the presence of pheochromocytoma was confirmed by MIBG scintigraphy. One or both adrenal glands were resected in five subjects; all contained pheochromocytomas. The sixth subject (Family D, Subject III-6) was asymptomatic and chose to postpone adrenalectomy.
Parathyroid Disease
Nine patients had elevated serum calcium concentrations, but in only three were the elevations persistent. Subject IV-25 in Family A had a parathyroid adenoma removed, and Subjects V-4 and V-16 in Family B had persistently elevated serum concentrations of calcium and parathyroid hormone but have not yet had surgery.
Non-MEN2A Gene Carriers with Positive Calcitonin Stimulation Tests
Six family members with MEN-2A (Family A, Subjects IV-19, IV-21, IV-26, V-48, and V-49, and Family C, Subject IV-6) who underwent total thyroidectomy on the basis of positive plasma calcitonin stimulation tests later proved not to be MEN2A gene carriers on the basis of DNA analysis.
Histologic examination of the thyroid glands in these subjects revealed only C-cell hyperplasia (Table 2). This was most often evident as focal collections of C cells interspersed among the thyroid cells and bounded by the basement membrane of the thyroid follicle (Figure 3F), but in some areas the C cells formed a ring completely surrounding the lumen of the follicle. There were numerous clusters containing up to 30 C cells in the upper poles of all the thyroid glands in these subjects. Two subjects (Family A, Subjects V-48 and V-49) had nodules containing 94 and 100 C cells, respectively.
Discussion
DNA analysis for the detection of mutations in the RET gene was a highly reliable method for the identification of subjects with MEN-2A. There have been no false positive results so far. This fact indicates a very high specificity and suggests that therapeutic decisions can be based on the results of DNA analysis, even in asymptomatic family members with negative biochemical tests for C-cell hyperplasia. The sensitivity of DNA analysis also appears high. There were no false negative test results (i.e., proved medullary thyroid carcinomas or other manifestations of MEN-2A without MEN2A-specific RET mutations) in the families we studied. These results make the test very useful as a means of excluding the possibility of genetic susceptibility to the development of the MEN-2A syndrome and therefore of assuring unaffected family members that further screening with biochemical or imaging tests can safely be abandoned.
The use of DNA analysis reveals the limitations of the plasma calcitonin stimulation test. DNA analysis can identify patients who have medullary thyroid carcinoma but who do not have positive stimulation-test results. We were surprised to find a number of young MEN2A gene carriers with medullary thyroid carcinoma (stage 1 thyroid cancer) and not just C-cell hyperplasia35. On the other hand, six family members who were later proved not to be gene carriers had positive stimulation tests and therefore underwent thyroidectomy. They had only C-cell hyperplasia, which occurs in normal subjects at a frequency of about 5 percent24,36-39. These results indicate that the plasma calcitonin responses to stimulation do not always distinguish C-cell hyperplasia from small carcinomas, a finding that limits the value of the stimulation test as far as detecting the presence of medullary thyroid carcinoma is concerned25.
Early expression of the mutated RET proto-oncogene in MEN2A gene carriers apparently results in multicentric C-cell lesions. However, no causal relation between specific RET mutations and medullary thyroid carcinoma or pheochromocytoma has yet been established by functional testing of the mutated RET genes in cultured cells or animals. Additional mutations in the RET gene or in other genes may be required for tumor formation. The appearance of tumors is thus unpredictable. The discovery of particular germ-line mutations of the RET proto-oncogene cosegregating with MEN-2A, MEN-2B, and familial medullary thyroid carcinoma in specific families permits reliable DNA diagnosis and presymptomatic treatment of medullary thyroid carcinoma.
Because of the high penetrance of medullary thyroid carcinoma in families with MEN-2A, it could be argued that total thyroidectomy at a very young age is indicated. However, the risk of complications of surgery (i.e., recurrent nerve paralysis and hypoparathyroidism) in young children in these families is probably not counterbalanced by the gain that accrues from the prevention of medullary thyroid carcinoma. The majority of our patients who were operated on after their plasma calcitonin stimulation tests became positive have not had a recurrence of the disease. Therefore, in general it still seems justified to postpone surgery until the results of the stimulation test become positive or until the age of 12 to 13 years, provided that periodic examinations are conducted. This program should relieve the parents of the psychological burden of postponing surgery.
The results of this study indicate that, as compared with biochemical testing, DNA analysis is a superior method of identifying subjects at risk for the components of the MEN-2A syndrome. The identification of gene carriers by this means should allow earlier identification of subjects at risk. Conversely, the identification of persons in affected families who are not gene carriers will spare them the need for periodic screening and the anxiety that attends the knowledge that they are at risk.
Supported by a grant from the Dutch Prevention Fund, The Hague, the Netherlands.
We are indebted to Ad Alleman, Marcel Smits, Albert Struyvenberg, and Jaap Van der Sluys Veer, our former colleagues; to Nico M.A. Bax, M.D., Maarten Jansen, M.D., and Jan-Maarten Wit, M.D., of the Departments of Medicine and Surgery, Wilhelmina Children's Hospital, Utrecht; to Frederik Bosman, M.D., Bert Ooms, M.D., and Werner H. Minder, M.D., for their excellent support with pathological examinations; to Erik P. Krenning, M.D., Sabine M.P.F. de Muinck Keizer-Schrama, and Bert Vermey, M.D., for contributing data on their patients; to Herman J.M. Van Rijn, Ph.D., Joop Seelen, Ph.D., and Mimi van Loon, for determinations of urinary catecholamines and metabolites; to Marinus A. Blankenstein, Ph.D., Willem H.L. Hackeng, Ph.D., Mariette Sprong, and Jos H.H. Thijssen, Ph.D., for the immunochemical determination of calcitonin; to Bruce A.J. Ponder, for providing information on CA repeats for the DNA-linkage studies; to Anne Huybers, Angelique Nortier, and Gerda Scheffer, for clinical assistance; to Ingrid G.J. Jansen, for the artwork; and to the families and general practitioners who participated in the study, for their cooperation.
Source Information
From the Departments of Internal Medicine (C.J.M.L., R.M.L., J.W.M.H., R.A.G., G.B., J.M.J.-S.V., M.J.W., R.A.Z.), Radiology (A.P.G.G.), Surgery (T.J.M.V.V.), and Pathology (R.M.L., J.W.M.H., M.J.W., R.A.Z., T.M.V.), University Hospital Utrecht, Utrecht; the Department of Pathology, Westeinde Hospital, The Hague (M.J.H.B.); and the Clinical Genetics Center, Utrecht (F.A.B., J.B.-S., R.P.M.J., H.K.P.A.) -- all in the Netherlands.
Address reprint requests to Dr. Lips at the Department of Internal Medicine, University Hospital Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
- References
References
1
Sipple JH . The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 1961;31:163-166
CrossRef | Web of Science2
Steiner AL ,Goodman AD ,Powers SR . Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore) 1968;47:371-409
CrossRef | Web of Science | Medline3
Schimke RN ,Hartmann WH ,Prout TE ,Rimoin DL . Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas: a possible regulatory defect in the differentiation of chromaffin tissue. N Engl J Med 1968;279:1-7
Full Text | Web of Science | Medline4
Carney JA ,Sizemore GW ,Lovestedt SA . Mucosal ganglioneuromatosis, medullary thyroid carcinoma, and pheochromocytoma: multiple endocrine neoplasia, type 2b. Oral Surg Oral Med Oral Pathol 1976;41:739-752
CrossRef | Medline5
Farndon JR ,Leight GS ,Dilley WG , et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 1986;73:278-281
CrossRef | Web of Science | Medline6
Jackson CE ,Norum RA . Genetic mechanisms of neoplasia in MEN 2. Henry Ford Hosp Med J 1989;37:116-119
Medline7
Lairmore TC ,Howe JR ,Korte JA , et al. Familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2B map to the same region of chromosome 10 as multiple endocrine neoplasia type 2A. Genomics 1991;9:181-192[Erratum, Genomics 1991;10:514.]
CrossRef | Web of Science | Medline8
Wolfe HJ ,Melvin KE ,Cervi-Skinner SJ , et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 1973;289:437-441
Full Text | Web of Science | Medline9
Hennessy JF ,Wells SA Jr ,Ontjes DA ,Cooper CW . A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1974;39:487-495
CrossRef | Web of Science | Medline10
Melvin KEW ,Miller HH ,Tashjian AH Jr . Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay. N Engl J Med 1971;285:1115-1120
Full Text | Web of Science | Medline11
Gagel RF ,Tashjian AH Jr ,Cummings T , et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a: an 18-year experience. N Engl J Med 1988;318:478-484
Full Text | Web of Science | Medline12
Mathew CGP ,Chin KS ,Easton DF , et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 1987;328:527-528
CrossRef | Web of Science | Medline13
Simpson NE ,Kidd KK ,Goodfellow PJ , et al. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 1987;328:528-530
CrossRef | Web of Science | Medline14
Mulligan LM ,Kwok JBJ ,Healy CS , et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-460
CrossRef | Web of Science | Medline15
Donis-Keller H ,Dou S ,Chi D , et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-856
CrossRef | Web of Science | Medline16
Hofstra RMW ,Landsvater RM ,Ceccherini I , et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-376
CrossRef | Web of Science | Medline17
Eng C ,Smith DP ,Mulligan LM , et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994;3:237-241
CrossRef | Web of Science | Medline18
Kwok JBJ ,Gardner E ,Warner JP ,Ponder BAJ ,Mulligan LM . Structural analysis of the human ret proto-oncogene using exon trapping. Oncogene 1993;8:2575-2582
Web of Science | Medline19
Iwamoto T ,Taniguchi M ,Asai N ,Ohkusu K ,Nakashima I ,Takahashi M . cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily. Oncogene 1993;8:1087-1091
Web of Science | Medline20
Vasen HFA ,Nieuwenhuijzen Kruseman A ,Berkel H , et al. Multiple endocrine neoplasia syndrome type 2: the value of screening and central registration: a study of 15 kindreds in the Netherlands. Am J Med 1987;83:847-852
CrossRef | Web of Science | Medline21
Lips CJM ,Minder WH ,Leo JR ,Alleman A ,Hackeng WHL . Evidence of multicentric origin of the multiple endocrine neoplasia syndrome type 2a (Sipple's syndrome) in a large family in the Netherlands: diagnostic and therapeutic implications. Am J Med 1978;64:569-578
CrossRef | Web of Science | Medline22
Lips KJM ,Van der Sluys Veer J ,Struyvenberg A ,Geerdink RA . Genetic predisposition to cancer in man: advantages and problems of central registration and screening of families at risk. Am J Med 1982;73:305-307
CrossRef | Web of Science | Medline23
van Gils APG ,Falke THM ,van Erkel AR , et al. MR imaging and MIBG scintigraphy of pheochromocytomas and extraadrenal functioning paragangliomas. Radiographics 1991;11:37-57
Web of Science | Medline24
Wolfe HJ ,Delellis RA . Familial medullary thyroid carcinoma and C cell hyperplasia. Clin Endocrinol Metab 1981;10:351-365
CrossRef | Medline25
Lips CJM ,Leo JR ,Berends MJH , et al. Thyroid C-cell hyperplasia and micronodules in close relatives of MEN-2A patients: pitfalls in early diagnosis and reevaluation of criteria for surgery. Henry Ford Hosp Med J 1987;35:133-138
Medline26
Landsvater RM ,Rombouts AGM ,te Meerman GJ , et al. The clinical implications of a positive calcitonin test for C-cell hyperplasia in genetically unaffected members of an MEN2A kindred. Am J Hum Genet 1993;52:335-342
Web of Science | Medline27
Wu J ,Giuffra LA ,Goodfellow PJ , et al. The beta subunit locus of the human fibronectin receptor: DNA restriction fragment length polymorphism and linkage mapping studies. Hum Genet 1989;83:383-390
CrossRef | Web of Science | Medline28
Nakamura Y ,Lathrop M ,Bragg T , et al. An extended genetic linkage map of markers for human chromosome 10. Genomics 1988;3:389-392
CrossRef | Web of Science | Medline29
Ponder BAJ ,Mathew CGP ,Easton DF , et al. Molecular genetics of MEN 2A. Henry Ford Hosp Med J 1989;37:205-205 abstract.30
Liou GI ,Li Y ,Wang C ,Fong SL ,Bhattacharya S ,Bridges CDB . Bgl II RFLP recognized by a human IRBP cDNA localized to chromosome 10. Nucleic Acids Res 1987;15:3196-3196 abstract.
CrossRef | Web of Science | Medline31
Nakamura Y ,Carlson M ,Krapcho K , et al. Isolation and mapping of a polymorphic DNA sequence pMCK2 on chromosome 10 [D10S15]. Nucleic Acids Res 1988;16:374-374
CrossRef | Web of Science | Medline32
Howe JR ,Lairmore TC ,Mishra SK , et al. Improved predictive test for MEN2, using flanking dinucleotide repeats and RFLPs. Am J Hum Genet 1992;51:1430-1442
Web of Science | Medline33
Love DR ,Gardner E ,Ponder BAJ . A polymorphic dinucleotide repeat at the D10S141 locus. Hum Mol Genet 1993;2:491-491 abstract.
Web of Science | Medline34
Love DR ,Gardner E ,Ponder BAJ . A polymorphic dinucleotide repeat at the ZNF22 locus. Hum Mol Genet 1993;2:491-491 abstract.
Web of Science | Medline35
DeGroot LJ . Thyroid carcinoma. Med Clin North Am 1975;59:1233-1246
Web of Science | Medline36
Gibson WGH ,Peng T-C ,Croker BP . C-cell nodules in adult human thyroid: a common autopsy finding. Am J Clin Pathol 1981;75:347-350
Web of Science | Medline37
Gibson WGH ,Peng T-C ,Croker BP . Age-associated C-cell hyperplasia in the human thyroid. Am J Pathol 1982;106:388-393
Web of Science | Medline38
O'Toole K ,Fenoglio-Preiser C ,Pushparaj N . Endocrine changes associated with the human aging process. III. Effect of age on the number of calcitonin immunoreactive cells in the thyroid gland. Hum Pathol 1985;16:991-1000
CrossRef | Web of Science | Medline39
Scopsi L ,Di Palma S ,Ferrari C ,Holst JJ ,Rehfeld JF ,Rilke F . C-cell hyperplasia accompanying thyroid diseases other than medullary carcinoma: an immunocytochemical study by means of antibodies to calcitonin and somatostatin. Mod Pathol 1991;4:297-304
Web of Science | Medline
- Citing Articles (129)
Citing Articles
1
Anne Goriely, Andrew O.M. Wilkie. (2012) Paternal Age Effect Mutations and Selfish Spermatogonial Selection: Causes and Consequences for Human Disease. The American Journal of Human Genetics 90:2, 175-200
CrossRef2
Andreas Machens, Alf Spitschak, Kerstin Lorenz, Brigitte M. Pützer, Henning Dralle. (2011) Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation?. Clinical Endocrinology 75:6, 801-805
CrossRef3
Nicole M. Tyer, Glenn D. Braunstein, David Frishberg. (2011) Unusual Case of Multiple Endocrine Neoplasia Type 2A Syndrome without Medullary Thyroid Carcinoma. Endocrine Practice 17:2, e4-e7
CrossRef4
Takumi Kudo, Akira Miyauchi, Yasuhiro Ito, Tomonori Yabuta, Hiroyuki Inoue, Takuya Higashiyama, Chisato Tomoda, Mitsuhide Hirokawa, Nobuyuki Amino. (2011) Serum calcitonin levels with calcium loading tests before and after total thyroidectomy in patients with thyroid diseases other than medullary thyroid carcinoma. Endocrine Journal 58:3, 217-221
CrossRef5
Anouk Scholten, Jennifer M. J. Schreinemakers, Carolina R. C. Pieterman, Gerlof D. Valk, Menno R. Vriens, Inne H. M. Borel Rinkes. (2011) Evolution of Surgical Treatment of Primary Hyperparathyroidism in Patients with Multiple Endocrine Neoplasia Type 2A. Endocrine Practice 17:1, 7-15
CrossRef6
S Mukherjee, D Zakalik. (2011) RET codon 804 mutations in multiple endocrine neoplasia 2: genotype-phenotype correlations and implications in clinical management. Clinical Genetics 79:1, 1-16
CrossRef7
Elizabeth G. Grubbs, Steven G. Waguespack, Thereasa A. Rich, Yan Xing, Anita K. Ying, Douglas B. Evans, Jeffrey E. Lee, Nancy D. Perrier. (2010) Do the recent American Thyroid Association (ATA) Guidelines accurately guide the timing of prophylactic thyroidectomy in MEN2A?. Surgery 148:6, 1302-1310
CrossRef8
Friedhelm Raue, Karin Frank-Raue. (2010) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2. Expert Review of Endocrinology & Metabolism 5:6, 867-874
CrossRef9
Ismail Jatoi, John R. Benson, Siong-Seng Liau, Yijun Chen, Robin M. Cisco, Jeffrey A. Norton, Jeffrey F. Moley, Katherine W. Khalifeh, Michael A. Choti. (2010) The Role of Surgery in Cancer Prevention. Current Problems in Surgery 47:10, 750-830
CrossRef10
Jennifer M. J. Schreinemakers, Menno R. Vriens, Gerlof D. Valk, Jan-Willem B. Groot, John T. Plukker, Klaas (N.) M. A. Bax, Jaap F. Hamming, Rob B. Luijt, Daniel C. Aronson, Inne H. M. Borel Rinkes. (2010) Factors Predicting Outcome of Total Thyroidectomy in Young Patients with Multiple Endocrine Neoplasia Type 2: A Nationwide Long-Term Follow-up Study. World Journal of Surgery 34:4, 852-860
CrossRef11
Christian Godballe, Gita Jørgensen, Anne-Marie Gerdes, Annelise S. Krogdahl, Anne Tybjærg-Hansen, Finn C. Nielsen. (2010) Medullary thyroid cancer: RET testing of an archival material. European Archives of Oto-Rhino-Laryngology 267:4, 613-617
CrossRef12
Cornelis JM Lips, Wendy van Veelen, Thera P Links, Jo WM Höppener. (2009) Multiple endocrine neoplasia type 2. Expert Review of Endocrinology & Metabolism 4:5, 443-465
CrossRef13
Andreas Machens, Kerstin Lorenz, Henning Dralle. (2009) Individualization of Lymph Node Dissection in RET (Rearranged During Transfection) Carriers at Risk for Medullary Thyroid Cancer. Annals of Surgery 250:2, 305-310
CrossRef14
W. van Veelen, J. W. B. de Groot, D. S. Acton, R. M. W. Hofstra, J. W. M. Höppener, T. P. Links, C. J. M. Lips. (2009) Medullary thyroid carcinoma and biomarkers: past, present and future. Journal of Internal Medicine 266:1, 126-140
CrossRef15
Shawn M. Allen, Donald Bodenner, James Y. Suen, Gresham T. Richter. (2009) Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma. The Laryngoscope 119:7, 1303-1311
CrossRef16
Oskar Koperek, Astrid Prinz, Christian Scheuba, Bruno Niederle, Klaus Kaserer. (2009) Tenascin C in medullary thyroid microcarcinoma and C-cell hyperplasia. Virchows Archiv 455:1, 43-48
CrossRef17
2009. Thyroid Gland Testing. , 1-58.
CrossRef18
Rebecca L. Margraf, David K. Crockett, Patti M.F. Krautscheid, Ryan Seamons, Fernanda R.O. Calderon, Carl T. Wittwer, Rong Mao. (2009) Multiple endocrine neoplasia type 2 RET protooncogene database: Repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Human Mutation 30:4, 548-556
CrossRef19
P.E. Goretzki, D. Wirowski, K. Schwarz, P. Pohl, H. Böhner, A. Starke, B.J. Lammers. (2009) Indikation und Durchführung endokrin-chirurgischer Operationen. Der Chirurg 80:2, 122-129
CrossRef20
H. Dralle. (2009) Endokrine Chirurgie: Quo vadis?. Der Chirurg 80:2, 85-87
CrossRef21
RHONDA K. YANTISS, DONALD A. ANTONIOLI. 2009. Polyps of the Small Intestine. , 447-480.
CrossRef22
H. Dralle, A. Machens, K. Lorenz. (2008) Hereditäre Schilddrüsenkarzinome. Der Chirurg 79:11, 1017-1028
CrossRef23
Glenda G. Callender, Thereasa A. Rich, Nancy D. Perrier. (2008) Multiple Endocrine Neoplasia Syndromes. Surgical Clinics of North America 88:4, 863-895
CrossRef24
José Miguel Dora, Maria Heloisa Busi da Silva Canalli, Clarissa Capp, Márcia Khaled Puñales, José Gilberto H. Vieira, Ana Luiza Maia. (2008) Normal Perioperative Serum Calcitonin Levels in Patients with Advanced Medullary Thyroid Carcinoma: Case Report and Review of the Literature. Thyroid 18:8, 895-899
CrossRef25
Tawakalitu Oseni, Ismail Jatoi. (2008) An Overview of the Role of Prophylactic Surgery in the Management of Individuals with a Hereditary Cancer Predisposition. Surgical Clinics of North America 88:4, 739-758
CrossRef26
Elizabeth G. Grubbs, Thereasa A. Rich, Guojun Li, Erich M. Sturgis, Maher N. Younes, Jeffrey N. Myers, Beth Edeiken-Monroe, Bruno D. Fornage, Douglas P. Monroe, Gregg A. Staerkel, Michelle D. Williams, Steven G. Waguespack, Mimi I. Hu, Gilbert Cote, Robert F. Gagel, James Cohen, Randal S. Weber, Daniel A. Anaya, F. Chris Holsinger, Nancy D. Perrier, Gary L. Clayman, Douglas B. Evans. (2008) Recent Advances in Thyroid Cancer. Current Problems in Surgery 45:3, 156-250
CrossRef27
STEVEN D. CHERNAUSEK, CHARIS ENG. 2008. Pheochromocytoma and the Multiple Endocrine Neoplasia Syndromes. , 512-529.
CrossRef28
Y. Nancy You, Vipul Lakhani, Samuel A. Wells. (2007) New Directions in the Treatment of Thyroid Cancer. Journal of the American College of Surgeons 205:4, S45-S48
CrossRef29
Murat Faik Erdogan, Alptekin Gursoy, Sevim Gullu, Semih Aydintug, Babur Kucuk, Nilgun Baskal, Nuri Kamel, Wolfgang Hoppner, Gurbuz Erdogan. (2007) Clinical and Genetic Experience in Turkish Multiple Endocrine Neoplasia Type 2 Families. The Endocrinologist 17:5, 273-277
CrossRef30
Jennifer D Holman, Jonathan A Dyer. (2007) Genodermatoses with malignant potential. Current Opinion in Pediatrics 19:4, 446-454
CrossRef31
Andreas Machens, Henning Dralle. (2007) Genotype-Phenotype Based Surgical Concept of Hereditary Medullary Thyroid Carcinoma. World Journal of Surgery 31:5, 957-968
CrossRef32
Y. Nancy You, Vipul T. Lakhani, Samuel A. Wells. (2007) The Role of Prophylactic Surgery in Cancer Prevention. World Journal of Surgery 31:3, 450-464
CrossRef33
Malcolm H Wheeler. (2007) Impact of genetic screening on the diagnosis and management of medullary thyroid carcinoma. Expert Review of Endocrinology & Metabolism 2:2, 117-119
CrossRef34
Amy Bui, Ernest L. Mazzaferri. (2007) New Paradigms in the Diagnosis and Management of Thyroid Nodules. The Endocrinologist 17:1, 35-45
CrossRef35
Maria João Bugalho, Rita Domingues, Jorge Rosa Santos, Ana Luísa Catarino, Luís Sobrinho. (2007) Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery 141:1, 90-95
CrossRef36
P. Miccoli, R. Elisei, G. Donatini, G. Materazzi, P. Berti. (2007) Video-assisted central compartment lymphadenectomy in a patient with a positive RET oncogene: initial experience. Surgical Endoscopy 21:1, 120-123
CrossRef37
Ronald A. DeLellis. (2006) Medullary Thyroid Carcinoma. Pathology Case Reviews 11:6, 243-255
CrossRef38
Andreas Machens, Steffen Hauptmann, Henning Dralle. (2006) Disparities between male and female patients with thyroid cancers: sex difference or gender divide?. Clinical Endocrinology 65:4, 500-505
CrossRef39
José G. Guillem, William C. Wood, Jeffrey F. Moley, Andrew Berchuck, Beth Y. Karlan, David G. Mutch, Robert F. Gagel, Jeffrey Weitzel, Monica Morrow, Barbara L. Weber, Francis Giardiello, Miguel A. Rodriguez-Bigas, James Church, Stephen Gruber, Kenneth Offit. (2006) ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes. Annals of Surgical Oncology 13:10, 1296-1321
CrossRef40
An T.T. Nguyen, Margaret R. Zacharin, Margaret Smith, Winita Hardikar. (2006) Isolated intestinal ganglioneuromatosis with a new mutation of RET proto-oncogene. European Journal of Gastroenterology & Hepatology 18:7, 803-805
CrossRef41
Jessica E. Gosnell, Mark S. Sywak, Stan B. Sidhu, Ian R. Gough, Diana L. Learoyd, Bruce G. Robinson, Leigh W. Delbridge. (2006) NEW ERA: PROPHYLACTIC SURGERY FOR PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA-2A. ANZ Journal of Surgery 76:7, 586-590
CrossRef42
Gill Spyer, Sian Ellard, Peter D. Turnpenny, Andrew T. Hattersley, Bijay Vaidya. (2006) Phenotypic Multiple Endocrine Neoplasia Type 2B, Without Endocrinopathy or RET Gene Mutation: Implications for Management. Thyroid 16:6, 605-608
CrossRef43
Robert Arnulf Wahl, Christian Vorländer, Susanne Kriener, Johanna Pedall, Martin Spitza, Martin-Leo Hansmann. (2006) Isthmus-Preserving Total Bilobectomy: An Adequate Operation for C-Cell Hyperplasia. World Journal of Surgery 30:5, 860-871
CrossRef44
Andreas Machens, Henning Dralle. (2006) Multiple endocrine neoplasia type 2 and the RET protooncogene: From bedside to bench to bedside. Molecular and Cellular Endocrinology 247:1-2, 34-40
CrossRef45
A. Frilling, F. Weber. (2006) Prophylaktische Chirurgie der Schilddrüse. Der Chirurg 77:1, 6-14
CrossRef46
Diana L. Learoyd, Jessica Gosnell, Marianne S. Elston, Tricia J. Saurine, Anne-Louise Richardson, Leigh W. Delbridge, John V. aglen, Bruce G. Robinson. (2005) Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clinical Endocrinology 63:6, 636-641
CrossRef47
Diana L Learoyd, Bruce G Robinson. (2005) Do all patients with RET mutations associated with multiple endocrine neoplasia type 2 require surgery?. Nature Clinical Practice Endocrinology & Metabolism 1:2, 60-61
CrossRef48
(2005) Letters to the Editor. Thyroid 15:10, 1203-1207
CrossRef49
Maria A. Kouvaraki, Suzanne E. Shapiro, Nancy D. Perrier, Gilbert J. Cote, Robert F. Gagel, Ana O. Hoff, Steven I. Sherman, Jeffrey E. Lee, Douglas B. Evans. (2005) RET Proto-Oncogene: A Review and Update of Genotype–Phenotype Correlations in Hereditary Medullary Thyroid Cancer and Associated Endocrine Tumors. Thyroid 15:6, 531-544
CrossRef50
Syed A. Ahmed, Karen Snow-Bailey, W. Edward Highsmith, Weimin Sun, Raymond G. Fenwick, Rong Mao. (2005) Nine Novel Germline Gene Variants in the RET Proto-Oncogene Identified in Twelve Unrelated Cases. The Journal of Molecular Diagnostics 7:2, 283-288
CrossRef51
S.L. Hyer, K. Newbold, C. Harmer. (2005) Familial medullary thyroid cancer: clinical aspects and prognosis. European Journal of Surgical Oncology (EJSO) 31:4, 415-419
CrossRef52
Frank J. Quayle, Jeffrey F. Moley. (2005) Medullary thyroid carcinoma: Including MEN 2A and MEN 2B syndromes. Journal of Surgical Oncology 89:3, 122-129
CrossRef53
M. Sara Rosenthal, Heather Hanson Pierce. (2005) Inherited Medullary Thyroid Cancer and the Duty to Warn: Revisiting Pate v. Threlkel in Light of HIPAA. Thyroid 15:2, 140-145
CrossRef54
C. J. LIPS, J. W. HOPPENER, B. P. VAN NESSELROOIJ, R. B. VAN DER LUIJT. (2005) Counselling in multiple endocrine neoplasia syndromes: from individual experience to general guidelines. Journal of Internal Medicine 257:1, 69-77
CrossRef55
A. MACHENS, J. UKKAT, M. BRAUCKHOFF, O. GIMM, H. DRALLE. (2005) Advances in the management of hereditary medullary thyroid cancer. Journal of Internal Medicine 257:1, 50-59
CrossRef56
Oliver Gimm, J
rg Ukkat, Barbara E. Niederle, Theresa Weber, Phuong Nguyen Thanh, Michael Brauckhoff, Bruno Niederle, Henning Dralle. (2004) Timing and Extent of Surgery in Patients with Familial Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia 2A-related RET Mutations Not Affecting Codon 634. World Journal of Surgery 28:12, 1312-1316
CrossRef57
O Beck, WJ Fassbender, P Beyer, S Kriener, HPH Neumann, T Klingebiel, T Lehrnbecher. (2004) Pheochromocytoma in childhood: implication for further diagnostic procedures. Acta Paediatrica 93:12, 1630-1634
CrossRef58
DM Gilchrist, DW Morrish, PJ Bridge, JL Brown. (2004) Cost analysis of DNA-based testing in a large Canadian family with multiple endocrine neoplasia type 2. Clinical Genetics 66:4, 349-352
CrossRef59
Henry T. Lynch, Trudy G. Shaw, Jane F. Lynch. (2004) Inherited predisposition to cancer: A historical overview. American Journal of Medical Genetics 129C:1, 5-22
CrossRef60
Jeffrey C. Buehler, Gordon C. Hunt. 2004. Multiple Endocrine Neoplasia (MEN). , 676-680.
CrossRef61
Maria João Bugalho, Rita Domingues, Luís Sobrinho. (2003) Molecular diagnosis of multiple endocrine neoplasia Type 2. Expert Review of Molecular Diagnostics 3:6, 769-779
CrossRef62
Machens, Andreas, Niccoli-Sire, Patricia, Hoegel, Josef, Frank-Raue, Karin, van Vroonhoven, Theo J., Roeher, Hans-Dietrich, Wahl, Robert A., Lamesch, Peter, Raue, Friedhelm, Conte-Devolx, Bernard, Dralle, Henning, . (2003) Early Malignant Progression of Hereditary Medullary Thyroid Cancer. New England Journal of Medicine 349:16, 1517-1525
Full Text63
Cote, Gilbert J., Gagel, Robert F., . (2003) Lessons Learned from the Management of a Rare Genetic Cancer. New England Journal of Medicine 349:16, 1566-1568
Full Text64
D.S. Kim, C.J. McCabe, M.A. Buchanan, J.C. Watkinson. (2003) Oncogenes in thyroid cancer. Clinical Otolaryngology and Allied Sciences 28:5, 386-395
CrossRef65
Andreas Machens, Hans-Jürgen Holzhausen, Phuong Nguyen Thanh, Henning Dralle. (2003) Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 134:3, 425-431
CrossRef66
Jeffrey F. Moley. (2003) Medullary thyroid carcinoma. Current Treatment Options in Oncology 4:4, 339-347
CrossRef67
M Skinner. (2003) Management of hereditary thyroid cancer in children. Surgical Oncology 12:2, 101-104
CrossRef68
Rhonda K. Yantiss, Robert D. Odze, Francis A. Farraye, Andrew E. Rosenberg. (2003) Solitary Versus Multiple Carcinoid Tumors of the Ileum. The American Journal of Surgical Pathology 27:6, 811-817
CrossRef69
M. S. Cohen, J. F. Moley. (2003) Surgical treatment of medullary thyroid carcinoma*. Journal of Internal Medicine 253:6, 616-626
CrossRef70
Nadia A. Chuzhanova, Emmanuel J. Anassis, Edward V. Ball, Michael Krawczak, David N. Cooper. (2003) Meta-analysis of indels causing human genetic disease: mechanisms of mutagenesis and the role of local DNA sequence complexity. Human Mutation 21:1, 28-44
CrossRef71
Oliver Gimm, Barbara E Niederle, Theresa Weber, Maximilian Bockhorn, Jörg Ukkat, Michael Brauckhoff, Phuong Nguyen Thanh, Andreja Frilling, Ernst Klar, Bruno Niederle, Henning Dralle. (2002) RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2A syndrome?. Surgery 132:6, 952-959
CrossRef72
McCLELLAN M. WALTHER. (2002) New Therapeutic and Surgical Approaches for Sporadic and Hereditary Pheochromocytoma. Annals of the New York Academy of Sciences 970:1, 41-53
CrossRef73
L. Michael Brunt, Terry C. Lairmore, Gerard M. Doherty, Mary A. Quasebarth, Mary DeBenedetti, Jeffrey F. Moley. (2002) Adrenalectomy for Familial Pheochromocytoma in the Laparoscopic Era. Annals of Surgery 235:5, 713-721
CrossRef74
Malcolm M. Bilimoria. (2002) Prophylactic surgery in hereditary cancer syndromes: An ounce of prevention may be the only cure. Journal of Surgical Oncology 79:3, 131-133
CrossRef75
Gabriela E. Sanso, Horacio M. Domene, Maria C. Garcia Rudaz, Eduardo Pusiol, Ana K. de Mondino, Maria Roque, Alejandro Ring, Hector Perinetti, Boris Elsner, Sonia Iorcansky, Marta Barontini. (2002) Very early detection ofRET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children. Cancer 94:2, 323-330
CrossRef76
Ellen Giarelli. (2002) Multiple endocrine neoplasia type 2a (MEN2a): a call for psycho-social research. Psycho-Oncology 11:1, 59-73
CrossRef77
Anne Bachelot, Francesca Lombardo, Eric Baudin, Jean-Michel Bidart, Martin Schlumberger. (2002) Inheritable forms of medullary thyroid carcinoma. Biochimie 84:1, 61-66
CrossRef78
Steven W.J. Lamberts, Leo J. Hofland, Frank R.E. Nobels. (2001) Neuroendocrine Tumor Markers. Frontiers in Neuroendocrinology 22:4, 309-339
CrossRef79
Weitzel, Jeffrey N., McCahill, Laurence E., . (2001) The Power of Genetics to Target Surgical Prevention. New England Journal of Medicine 344:25, 1942-1944
Full Text80
Efisio Puxeddu, James A. Fagin. (2001) GENETIC MARKERS IN THYROID NEOPLASIA. Endocrinology & Metabolism Clinics of North America 30:2, 493-513
CrossRef81
Debra H Schussheim, Monica C Skarulis, Sunita K Agarwal, William F Simonds, A.Lee Burns, Allen M Spiegel, Stephen J Marx. (2001) Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends in Endocrinology & Metabolism 12:4, 173-178
CrossRef82
Giovanni Vitale, Michele Caraglia, Antonio Ciccarelli, Gelsy Lupoli, Alberto Abbruzzese, Pierosandro Tagliaferri, Giovanni Lupoli. (2001) Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 91:9, 1797-1808
CrossRef83
A.F. Carli, F. Mariani, L. Di Cosmo, R. Giuli, A. Neri. (2001) Familial medullary thyroid carcinoma (FMTC). Study of one family (treatment criteria). European Journal of Surgical Oncology (EJSO) 27:2, 162-164
CrossRef84
Oliver Gimm. (2001) Thyroid cancer. Cancer Letters 163:2, 143-156
CrossRef85
D. L. Learoyd, L. W. Delbridge, B. G. Robinson. (2000) Multiple endocrine neoplasia. Australian and New Zealand Journal of Medicine 30:6, 675-682
CrossRef86
Frans J.M. Grosfeld, Frits A. Beemer, Cornelis J.M. Lips, Karin S.W.H. Hendriks, Herman F.J. ten Kroode. (2000) Parents' responses to disclosure of genetic test results of their children. American Journal of Medical Genetics 94:4, 316-323
CrossRef87
Hanne Sand Hansen, Helle T
CrossRef88
Koper, J. Lamberts. (2000) Sporadic endocrine tumours and their relationship to the hereditary endocrine neoplasia syndromes. European Journal of Clinical Investigation 30:6, 493-500
CrossRef89
Jo Ellen Krueger, Anirban Maitra, Jorge Albores-Saavedra. (2000) Inherited Medullary Microcarcinoma of the Thyroid. The American Journal of Surgical Pathology 24:6, 853-858
CrossRef90
Frans J.M. Grosfeld, Cornelis J.M. Lips, Frits A. Beemer, Geert H. Blijham, Jac M.S.P. Quirijnen, Michiel P. Mastenbroek, Herman F.J. ten Kroode. (2000) Distress in MEN 2 family members and partners prior to DNA test disclosure. American Journal of Medical Genetics 91:1, 1-7
CrossRef91
Toshihide Iwashita, Hideki Murakami, Kei Kurokawa, Kumi Kawai, Akira Miyauchi, Hitoyasu Futami, Shanlou Qiao, Masatoshi Ichihara, Masahide Takahashi. (2000) A Two-Hit Model for Development of Multiple Endocrine Neoplasia Type 2B by RET Mutations. Biochemical and Biophysical Research Communications 268:3, 804-808
CrossRef92
Shinya Uchino, Shiro Noguchi, Mari Sato, Mitsuo Adachi, Hiroyuki Yamashita, Shin Watanabe, Tsukasa Murakami, Masakatsu Toda, Nobuo Murakami, Hiroto Yamashita. (1999) Presymptomatic detection and treatment of Japanese carriers of the multiple endocrine neoplasia type 2A gene. Surgery Today 29:9, 862-867
CrossRef93
E. Modigliani. (1999) Le cancer médullaire de la thyroïde. La Revue de Médecine Interne 20:6, 490-503
CrossRef94
ELECTRON KEBEBEW, PATRICK A. TRESLER, ALLAN E. SIPERSTEIN, QUAN-YANG DUH, ORLO H. CLARK. (1999) Normal Thyroid Pathology in Patients Undergoing Thyroidectomy for Finding a RETgene Germline Mutation: A Report of Three Cases and Review of the Literature. Thyroid 9:2, 127-131
CrossRef95
D. A. O’Keeffe, A. D. K. Hill, E. W. McDermott, N. J. O’Higgins, K. Sheahan, F. Ryan, D. Barton, R. J. Fitzgerald. (1998) Ret-proto-oncogene analysis in medullary thyroid carcinoma. Irish Journal of Medical Science 167:4, 226-230
CrossRef96
Josep Oriola, Concepci
CrossRef97
Shiu-Ru Lin, Yuan-Chieh Yang, Juei-Hsiung Tsai, Chin-Hsun Hsu. (1998) Alterations of RET, Oncogene in Human Adrenal Tumors. Cancer Science 89:6, 634-640
CrossRef98
Lips. (1998) Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease. Journal of Internal Medicine 243:6, 589-594
CrossRef99
J. Thuróczy, F.J. van Sluijs, H.S. Kooistra, G. Voorhout, J.A. Mol, J.S. van der Linde‐Sipman, A. Rijnberk. (1998) Multiple endocrine neoplasias in a dog: Corticotrophic tumour, bilateral adrenocortical tumours, and pheochromocytoma. Veterinary Quarterly 20:2, 56-61
CrossRef100
F.J.M. Grosfeld, C.J.M. Lips, F.A. Beemer, H.G. van Spijker, G.J. Brouwers-Smalbraak, H.F.J. ten Kroode. (1997) Psychological risks of genetically testing children for a hereditary cancer syndrome. Patient Education and Counseling 32:1-2, 63-67
CrossRef101
Ruth A. Decker, Michael L. Peacock. (1997) Update on the profile of multiple endocrine neoplasia type 2aRET mutations. Cancer 80:S3, 557-568
CrossRef102
M. ALEVIZAKI, H. SARIKA, D. A. KOUTRAS, A. SOUVATZOGLOU. (1997) Genetic Screening for RET Mutations in Families with Multiple Endocrine Neoplasia 2 Syndromes. Annals of the New York Academy of Sciences 816:1 Adolescent Gy, 383-388
CrossRef103
Jeffrey F. Moley, MD. (1997) THE MOLECULAR GENETICS OF MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A AND RELATED SYNDROMES. Annual Review of Medicine 48:1, 409-420
CrossRef104
Lara M. Boccia, Jane S. Green, Carol Joyce, Charts Eng, Sherryl A. M. Taylor, Lois M. Mulligan. (1997) Mutation of RET codon 768 is associated with the FMTC phenotype. Clinical Genetics 51:2, 81-85
CrossRef105
F. Raue, Karin Frank-Raue. (1997) Biochemical parameters in diagnosis and follow-up of patients with multiple endocrine neoplasia type 2. European Surgery 29:1, 9-11
CrossRef106
Claudia Franz, S. A. Wells. (1997) Prophylactic thyroidectomy in MEN 2 gene carriers. European Surgery 29:1, 12-14
CrossRef107
Søren Schifter. (1997) Expression of the Calcitonin Gene Family in Medullary Thyroid Carcinoma. Peptides 18:2, 307-317
CrossRef108
Charis Eng, Lois M. Mulligan. (1997) Mutations of theRET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Human Mutation 9:2, 97-109
CrossRef109
Charis Eng. (1997) Genetic screening in hereditary medullary thyroid carcinoma. European Surgery 29:1, 5-8
CrossRef110
P. E. Goretzki, D. Simon, Cornelia Dotzenrath, H. -D. Röher. (1996) Surgery for pheochromocytoma in MEN II patients— a radical versus a limited approach. European Surgery 28:5, 296-299
CrossRef111
Flier, Jeffrey S., Underhill, Lisa H., Eng, Charis, . (1996) The RET Proto-Oncogene in Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease. New England Journal of Medicine 335:13, 943-951
Full Text112
Monika Fink, Andreas Weinhäusel, Bruno Niederle, Oskar A. Haas. (1996) Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of theRET proto-oncogene. International Journal of Cancer 69:4, 312-316
CrossRef113
J. W. M. HÖPPENER, C. J. M. LIPS. (1996) RET receptor tyrosine kinase gene mutations: molecular biological, physiological and clinical aspects. European Journal of Clinical Investigation 26:8, 613-624
CrossRef114
Robert M. W. Hofstra, Rolf H. Sijmons, Tineke Stelwagen, Rein P. Stulp, Boris G. Kousseff, Cornelis J. M. Lips, Peter M. Steijlen, Pieter C. van Voorst Vader, Charles H. C. M. Buys. (1996) RET Mutation Screening in Familial Cutaneous Lichen Amyloidosis and in Skin Amyloidosis Associated With Multiple Endocrine Neoplasia.. Journal of Investigative Dermatology 107:2, 215-218
CrossRef115
B. T. Teh, J. Hansen, P.-J. Svensson, L. Hartley. (1996) Bilateral recurrent phaeochromocytoma associated with a growth hormone-secreting pituitary tumour. British Journal of Surgery 83:8, 1132-1132
CrossRef116
Toshirou Nishida, Kazuyasu Nakao, Masayasu Hamaji, Masa-aki Nakahara, Masahiko Tsujimoto. (1996) Overexpression of p53 protein and DNA content are important biologic prognostic factors for thyroid cancer. Surgery 119:5, 568-575
CrossRef117
Massimo E. Dottorini, Agnese Assi, Maria Sironi, Gabriele Sangalli, Gianluigi Spreafico, Luigia Colombo. (1996) Multivariate analysis of patients with medullary thyroid carcinoma: Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77:8, 1556-1565
CrossRef118
SISSY M. JHIANG, LINDA FITHIAN, CHRISTOPHER M. WEGHORST, ORLO H. CLARK, JAMES M. FALKO, THOMAS M. O'DORISIO, ERNEST L. MAZZAFERRI. (1996) RET Mutation Screening in MEN2 Patients and Discovery of a Novel Mutation in a Sporadic Medullary Thyroid Carcinoma. Thyroid 6:2, 115-121
CrossRef119
Arrie Perry, Kyle Molberg, Jorge Albores-Saavedra. (1996) Physiologic versus neoplastic C-cell hyperplasia of the thyroid: Separation of distinct histologic and biologic entities. Cancer 77:4, 750-756
CrossRef120
Marios Kambouris, Charles E. Jackson, Gerald L. Feldman. (1996) Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses ofRET proto-oncogene mutations. Human Mutation 8:1, 64-70
CrossRef121
Andrew A. Toogood, Charis Eng, Darrin P. Smith, Bruce A. J. Ponder, Stephen M. Shalet. (1995) No mutation at codon 918 of the RET gene in a family with multiple endocrine neoplasia type 2B. Clinical Endocrinology 43:6, 759-762
CrossRef122
Paul Komminoth, Seraina Muletta-Feurer, Parvin Saremaslani, Eva K. Kunz, Xavier Matias-Guiu, Olaf Hiort, Sören Schröder, Walter K. F. Seelentag, Jürgen Roth, Philipp U. Heitz. (1995) Molecular diagnosis of multiple endocrine neoplasia (MEN) in paraffin-embedded specimens. Endocrine Pathology 6:4, 267-278
CrossRef123
DEBBIE J. MARSH, DIANA L. LEAROYD, BRUCE G. ROBINSON. (1995) Medullary Thyroid Carcinoma: Recent Advances and Management Update. Thyroid 5:5, 407-424
CrossRef124
C. J. M. LIPS, R. M. LANDSVATER, J. W. M. HÖPPENER, R. A. GEERDINK, G. H. BLIJHAM, J. M. JANSEN-SCHILLHORN VEEN, M. A. M. FELDBERG, A. P. G. GILS, H. HOOGENBOOM, M. J. H. BERENDS, F. A. BEEMER, H.-K. PLOOS AMSTEL, T. J. M. V. VROONHOVEN, T. M. VROOM. (1995) From medical history and biochemical tests to presymptomatic treatment in a large MEN 2A family. Journal of Internal Medicine 238:4, 347-356
CrossRef125
Eva K. Kunz, Xavier Matias-Guiu, Olaf Hiort, Gudrun Christiansen, Anna Colomer, Jürgen Roth, Philipp U. Heitz, Paul Komminoth. (1995) Analysis ofRET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer 76:3, 479-489
CrossRef126
Gilbert J. Cote, Nelson Wohllk, Douglas Evans, Helmuth Goepfert, Robert F. Gagel. (1995) RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Baillière's Clinical Endocrinology and Metabolism 9:3, 609-630
CrossRef127
Charls Eng, Lois M. Mulligan, Darrin P. Smith, Catherine S. Healey, Andrea Frilling, Friedhelm Raue, Hartmut P.H. Neumann, Margaret A. Ponder, Bruce A.J. Ponder. (1995) Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clinical Endocrinology 43:1, 123-127
CrossRef128
Michael C. Sheppard. (1995) Should serum calcitonin be measured routinely in all patients with nodular thyroid disease?. Clinical Endocrinology 42:5, 451-452
CrossRef129
Utiger, Robert D., . (1994) Medullary Thyroid Carcinoma, Genes, and the Prevention of Cancer. New England Journal of Medicine 331:13, 870-871
Full Text
